Immunome to Showcase Novel ROR1-ADC at Major Oncology Symposium
Immunome's Groundbreaking Presentation on ADC Therapy
Today, Immunome, Inc. (Nasdaq: IMNM) is excited to announce its participation in a prominent oncology symposium where it will showcase the preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC). This innovative therapeutic approach could pave the way for enhanced cancer treatments, leveraging Immunome's expertise in targeted cancer therapies.
What is IM-1021?
IM-1021 is designed to target the receptor tyrosine kinase ROR1, which plays a critical role in the survival and proliferation of cancer cells. By utilizing a sophisticated drug conjugate technology, Immunome aims to deliver potent anti-cancer agents directly to tumor cells while minimizing damage to healthy tissue. This targeted strategy is central to the ongoing development of next-generation cancer therapies.
Anticipated FDA Submission
Immunome expects to submit an Investigational New Drug (IND) application for the IM-1021 program to the FDA in the near future. This proactive step is part of the company’s commitment to bringing new treatment options to patients battling cancer. By working within the stringent regulatory framework, Immunome aims to ensure the safety and efficacy of its innovative therapies.
Details of the Presentation
The poster presentation will be held at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Immunome's team is eager to share their findings with fellow researchers and industry professionals, highlighting the significance of their work in advancing ADCs.
Poster Presentation Specifics
Here are the key details regarding the presentation:
Title: Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload.
Presenter: Robert Lawrence, Director of Biology, Immunome
Date: Upcoming symposium date
Understanding Immunome, Inc.
As a clinical-stage oncology company, Immunome is committed to developing cutting-edge therapies designed to improve patient outcomes in cancer treatment. The leadership team brings substantial expertise from successful roles in the design and commercialization of advanced targeted therapies, particularly antibody-drug conjugates (ADCs).
Within its diverse pipeline, Immunome boasts not only IM-1021, but also AL102, a gamma secretase inhibitor currently in a Phase 3 trial for desmoid tumors, and IM-3050, a radioligand targeting fibroblast activation protein (FAP). Both of these candidates are under INDs expected to be submitted soon.
Looking Ahead
Immunome's ongoing research signifies a commitment to innovation and excellence in the field of oncology. The company’s aim is to harness the power of targeted therapies to transform cancer care. As advancements continue, stakeholders are watching closely to see how these innovative approaches will reshape the landscape of cancer treatment.
Frequently Asked Questions
What is the significance of IM-1021?
IM-1021 represents a novel approach to cancer therapy by targeting ROR1, potentially improving the precision and effectiveness of treatment.
When will Immunome submit its IND application?
The IND for the IM-1021 program is anticipated to be submitted in the first quarter of 2025.
Who will present the research at the symposium?
Robert Lawrence, the Director of Biology at Immunome, will be presenting the findings.
Where will the poster be available after the presentation?
A copy of the poster will be uploaded to Immunome's website in the “Events & Presentations” section.
What are Immunome's future plans?
Immunome plans to continue advancing its pipeline of targeted therapies, focusing on both regulatory submissions and clinical trials to enhance cancer treatment options.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exciting Launch of Hot Wheels Monster Trucks on All Platforms
- Biological Lattice Industries Lands Major Funding for Innovation
- Innovative Student Projects Shine at 2024 Collegiate Inventors Gala
- ADTRAN Holdings Set to Announce 2024 Q3 Earnings Soon
- Exciting Growth Ahead for REI Co-op with New Store Openings
- Genians Expands Operations with New Office in Dubai to Boost MEA Cybersecurity
- Ryan Murphy Celebrates Grand Opening of Swim School in Florida
- Hepsiburada Enters Agreement to Sell Class A and B Shares
- Transforming a Classic: The WhippleD Chevelle's Debut at SEMA
- Clockwork Sets Stage for Innovation at Major Industry Events
Recent Articles
- Helius Medical Technologies to Showcase Innovations at Key Conference
- Exciting New Home Community Launched by KB Home in Florida
- Alignment Healthcare Sets Stage for Q3 2024 Financial Call
- Vertex Pharmaceuticals Showcases Pivotal Phase 3 Data for Suzetrigine
- SpaceX and NASA Partner for Upcoming ISS Missions in 2025
- Madrigal Pharmaceuticals Plans Exciting Q3 Financial Results Event
- Ferring Pharmaceuticals Showcases Innovations in Fertility Care
- FOREWARN Partners with REALTORS® for Enhanced Safety Tools
- Bitcoin's Surge: Impact on Altcoins and Future Strategies
- Key Updates on Tryg Share Trading Activity Among Executives
- Cyber A.I. Group Partners to Drive Strategic Growth Initiatives
- Heliogen Welcomes Apurba Das as the New CTO to Drive Innovation
- Octopus Future Generations VCT Enhances Offering Strategy
- Helius Medical Technologies Highlights Innovations at Conference
- Valour's Strategic Shift to Spotlight to Boost ETP Market Presence
- Butterfly Network to Reveal Q3 2024 Results in Upcoming Call
- Alignment Healthcare Set to Reveal Q3 2024 Financials Soon
- Madrigal Pharmaceuticals' Upcoming Third-Quarter Results Webcast
- Pending Home Sales Surge Indicates a Shifting Market Trend
- Class Action Alert: Paragon 28 Faces Legal Challenges Ahead
- Republic Bancorp's Q3 2024 Performance: A Bright Future Ahead
- RXR and Hudson Bay Capital Join Forces for Prestigious Upgrade
- Exploring Undervalued Energy Stocks Poised for Growth
- Celebrating Indigenous Economic Excellence: The 2024 Winners
- LOST MARY Establishes Expert Advisory Board to Enhance Strategy
- Sierra Bancorp Unveils New Buyback Plan and Cash Dividend
- Pan Global Secures $7 Million Financing Amid High Demand
- Empowering Inclusive Futures: Nora Project's Training Initiative
- AffableBPM Joins Creative Destruction Lab to Transform Healthcare
- Laramide Enhances Financial Flexibility with New Lending Agreement
- cTRL Therapeutics to Showcase Innovative Cancer Treatment Data
- Ally Financial Shares Strong Third Quarter Results Announcement
- Centro Expands Its Platform to Redefine Broker-Carrier Dynamics
- MicroSalt Experiences Notable Share Price Increase Amid Updates
- Valvoline Inc. CFO Mary Meixelsperger to Retire Soon
- Piper Sandler Adjusts Microsoft Outlook Amidst Earnings Concerns
- OURHOME to Showcase Innovative K-Food at Major Event
- Gore Street Energy Storage Fund Secures Major $14M Contract
- TSC Alliance Celebrates 50 Years of Progress in TSC Support
- Future plc Faces Leadership Change as Jon Steinberg Resigns
- Tech Giants Show Gains; Financial Sector Faces Challenges
- Unexpected Trends in Holiday Travel This Season
- Nixxy's Strategic Spin-Off Sparks AI Innovations and Growth
- Transforming 620 Avenue of the Americas: A New Beginning
- Citi Cuts Liberty Oilfield Services to Neutral, Price Target Adjusted
- Highlighting Growth: Join New England's Fastest Companies
- Mizuho Boosts DraftKings Stock Target on Earnings Outlook
- Kahoot! Achieves Gold Certification in Educational Equity
- Optimistic Outlook for Aura Biosciences Following Positive Data
- Cytokinetics Maintains Strong Outlook Amid Positive Analyst Ratings